CN104010656B - 使用免疫球蛋白和c1-抑制剂的联合疗法 - Google Patents

使用免疫球蛋白和c1-抑制剂的联合疗法 Download PDF

Info

Publication number
CN104010656B
CN104010656B CN201280046349.8A CN201280046349A CN104010656B CN 104010656 B CN104010656 B CN 104010656B CN 201280046349 A CN201280046349 A CN 201280046349A CN 104010656 B CN104010656 B CN 104010656B
Authority
CN
China
Prior art keywords
inh
immunoglobulin
administered
ivig
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280046349.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104010656A (zh
Inventor
M·巴斯塔
陈新志
M·马特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Original Assignee
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland, US Department of Health and Human Services filed Critical CSL Behring GmbH Deutschland
Publication of CN104010656A publication Critical patent/CN104010656A/zh
Application granted granted Critical
Publication of CN104010656B publication Critical patent/CN104010656B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280046349.8A 2011-09-24 2012-09-21 使用免疫球蛋白和c1-抑制剂的联合疗法 Active CN104010656B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538832P 2011-09-24 2011-09-24
US61/538,832 2011-09-24
PCT/EP2012/068643 WO2013041677A1 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and c1-inhibitor

Publications (2)

Publication Number Publication Date
CN104010656A CN104010656A (zh) 2014-08-27
CN104010656B true CN104010656B (zh) 2016-02-24

Family

ID=46881067

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280046349.8A Active CN104010656B (zh) 2011-09-24 2012-09-21 使用免疫球蛋白和c1-抑制剂的联合疗法

Country Status (9)

Country Link
US (1) US10471142B2 (https=)
EP (1) EP2758076B1 (https=)
JP (1) JP6190368B2 (https=)
KR (1) KR101956585B1 (https=)
CN (1) CN104010656B (https=)
AU (1) AU2012311483B2 (https=)
DK (1) DK2758076T3 (https=)
ES (1) ES2714999T3 (https=)
WO (1) WO2013041677A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9352016B2 (en) 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
ES2609070T3 (es) * 2013-02-28 2017-04-18 Csl Behring Gmbh Agente terapéutico para el embolismo de líquido amniótico
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
EP4162947A1 (en) * 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
US20180036394A1 (en) * 2015-02-20 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2022251654A1 (en) * 2021-05-28 2022-12-01 West Virginia University Board of Governors on behalf of West Virginia University Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1750844A (zh) * 2003-02-21 2006-03-22 唐纳士公司 用于预防和治疗与局部缺血－再灌注损伤相关的组织损伤的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009158A (en) * 1934-08-01 1935-07-23 Ophthalmological Foundation In Ophthalmic ergograph
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
US20100143325A1 (en) * 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1750844A (zh) * 2003-02-21 2006-03-22 唐纳士公司 用于预防和治疗与局部缺血－再灌注损伤相关的组织损伤的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuroprotection in Stroke by Complement Inhibition and Immunoglobulin Therapy;Thiruma V. Arumugama et al.;《Neuroscience》;20090206;第158卷(第3期);1074-1089 *

Also Published As

Publication number Publication date
KR20140075753A (ko) 2014-06-19
HK1200334A1 (en) 2015-08-07
CA2848510A1 (en) 2013-03-28
US20140234293A1 (en) 2014-08-21
EP2758076B1 (en) 2018-12-12
AU2012311483B2 (en) 2016-03-10
KR101956585B1 (ko) 2019-03-11
JP2014526541A (ja) 2014-10-06
US10471142B2 (en) 2019-11-12
WO2013041677A1 (en) 2013-03-28
ES2714999T3 (es) 2019-05-31
EP2758076A1 (en) 2014-07-30
JP6190368B2 (ja) 2017-08-30
DK2758076T3 (en) 2019-04-01
CN104010656A (zh) 2014-08-27
AU2012311483A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
CN104010656B (zh) 使用免疫球蛋白和c1-抑制剂的联合疗法
JP7080263B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤
TWI831106B (zh) 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
Ishrat et al. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats
WO2012174055A1 (en) Wound healing using complement inhibitors
JP2015522630A (ja) 多発性硬化症治療のためのビオチンの使用
BR112015006189A2 (pt) anticorpo anti-gm-csf, composição farmacêutica, e, uso de um anticorpo anti-gm-csf na fabricação de um medicamento
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
Xiaohong et al. CFLAR is a critical regulator of cerebral ischaemia-reperfusion injury through regulating inflammation and endoplasmic reticulum (ER) stress
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
US20240358721A1 (en) Gasdermin-d inhibitors and uses thereof for treating pulmonary vaso-occlusion
NZ719724A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
Chen et al. Combination therapy with low-dose IVIG and a C1-esterase inhibitor ameliorates brain damage and functional deficits in experimental ischemic stroke
CN111447950B (zh) 活性调节剂
EA013008B1 (ru) Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с
JP2022125248A (ja) 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
JP2021522241A5 (https=)
CN104869994B (zh) 匹多莫德治疗银屑病的用途
WO2023222051A1 (zh) Mif和ripk1在围术期缺血性脑损伤中的应用
CA2848510C (en) Combination therapy using immunoglobulin and c1-inhibitor
HK1200334B (en) Combination therapy using immunoglobulin and c1-inhibitor
US20230338356A1 (en) Treatment of autoimmune skin disease
KR20240025512A (ko) 건선의 치료 방법
US20200062855A1 (en) Compositions and methods of promoting wound healing
TW201817426A (zh) 三萜混合物用以治療多發性硬化的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant